Research programme: oncostatin M therapeutics - Genodyssee
Alternative Names: GOOSMs; Oncostatin M variants - GenodyseeLatest Information Update: 07 Mar 2011
Price :
$50 *
At a glance
- Originator GenOdyssee
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 10 Apr 2006 Preclinical trials in Inflammation in France (unspecified route)
- 10 Apr 2006 Preclinical trials in Multiple sclerosis in France (unspecified route)
- 10 Apr 2006 Preclinical trials in Rheumatoid arthritis in France (unspecified route)